Bora Pharmaceuticals Injectables
United States
Hybrid — also manufactures internal programs
Program data pending ClinicalTrials.gov matching
Profiled
Not yet scored
✓ FDA Inspections (3)
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
✓ HC GMP (1)
Quick Facts: Bora Pharmaceuticals Injectables
- Signal Score
- Profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed. How scoring works
- Headquarters
- United States
- Website
- https://bora-corp.com/
- Modalities
- Sterile Fill-Finish
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
About Bora Pharmaceuticals Injectables
Bora Pharmaceuticals Injectables makes its own pharmaceutical products and also offers contract development and manufacturing services. Capabilities: Sterile Fill-Finish. 1 manufacturing site registered with the U.S. FDA and Health Canada. Website: https://bora-corp.com/
Signal Score
Profiled, not yet scored.
Scores are published after regulatory evidence is attached and reviewed.
How scoring works
Bora Pharmaceuticals Injectables FDA Inspection History
2024-07
2023-08
2022-02
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2024-07-25 |
Bora Pharmaceuticals Injectables Inc
Baltimore, Maryland
Company-level
|
Blood and Blood Products | No | No Action Indicated (NAI) |
| 2023-08-10 |
Bora Pharmaceuticals Injectables Inc
Baltimore, Maryland
Company-level
|
Drug Quality Assurance | No | Voluntary Action Indicated (VAI) |
| 2022-02-18 |
Bora Pharmaceuticals Injectables Inc
Baltimore, Maryland
Company-level
|
Drug Quality Assurance | No | Official Action Indicated (OAI) |
Source: FDA Data Dashboard · Retrieved Oct 31, 2026
Hiring Activity 9 open roles Beta
From public job postings on the parent company's careers board, as of Oct 30, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
9
open roles
6
in manufacturing, quality, PD/MSAT, engineering or regulatory (67%)
Trend from Nov 29, 2026
Tracking started Oct 30, 2026. 30-day change shows after 30 days, 90-day after Jan 28, 2027.
By function
By site
Baltimore
4 mfg/ops · 1 QA/QC · 1 eng. · 3 other 9
4 mfg/ops · 1 QA/QC · 1 eng. · 3 other 9
Latest postings
Supervisor Production
Manufacturing & operations · Baltimore
Specialist I, Quality Operations
Quality (QA / QC) · Baltimore
Senior Project Manager
Commercial, BD & client projects · Baltimore
Payroll Administrator
Other (finance, HR, IT, other) · Baltimore
Master Data Steward
Other (finance, HR, IT, other) · Baltimore
Manager, Process Maintenance
Engineering & facilities · Baltimore
Equipment Specialist 2nd Shift
Manufacturing & operations · Baltimore
Craftworker, Powerhouse, 2nd Shift
Manufacturing & operations · Baltimore
Assistant Technician, Inspection, Packaging 2nd Shift
Manufacturing & operations · Baltimore
Coverage: read from the parent company's careers board and kept only postings at this business's sites (group board filtered to the Baltimore injectables site (ex-Emergent Camden, acquired 2024)). Roles outside those sites are left out, and some of this unit's roles may be missed.
Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source:
boracorpcdmo.wd108.myworkdayjobs.com
· Checked Oct 30, 2026 · Tracking since Oct 30, 2026
Company Signals 10 articles
Company announcements, not verified evidence. They do not change any score.
Bora Group to acquire MacroGenics manufacturing for $122.5 million - Vietnam Investment Review - VIR
MacroGenics Sells Maryland Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million - citybiz
Bora Pharmaceuticals Posts Steady 2025 Growth; CDMO Revenue (incl. inter-company) Surges 53.8% - 全球醫療採購網
Bora Pharmaceuticals to Acquire MacroGenics Manufacturing Facility in $122.5 Million Deal - biobuzz.io
Bora snaps up MacroGenics’ manufacturing, CDMO operations for up to $127.5M - Fierce Pharma
CDMO Bora locks in 5-year, $250M production agreement with GSK - Fierce Pharma
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract - Business Wire
Bora Pharmaceuticals, GSK Renew Global Manufacturing Contract for $250M - Contract Pharma
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals - GlobeNewswire
Bora Pharmaceuticals marks five years in Mississauga with expanded CDMO capabilities and continued global growth - Manufacturing Chemist
Frequently Asked Questions About Bora Pharmaceuticals Injectables
How many FDA inspections does Bora Pharmaceuticals Injectables have on record?
CDMO Signal tracks 3 FDA inspections for Bora Pharmaceuticals Injectables, sourced from the FDA inspection database. See the full inspection history above.
Has Bora Pharmaceuticals Injectables received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Bora Pharmaceuticals Injectables.
Does Bora Pharmaceuticals Injectables have a CDMO Signal Score?
Not yet. Bora Pharmaceuticals Injectables is profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed.
Evaluating Bora Pharmaceuticals Injectables for a manufacturing program?
Use the free AI matchmaker to compare Bora Pharmaceuticals Injectables against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
Similar CDMOs
DPT Laboratories
San Antonio, Texas, United States
Semi-solids & Liquids, Non-sterile Liquids, Topicals, Finished Dosage Forms, Sterile Fill-Finish, Clinical Trial Manufacturing
Woodstock Sterile Solutions
United States
Sterile Fill-Finish
Sharp Services
United States
Packaging & Labeling, Sterile Fill-Finish
Vetio Animal Health
United States
Oral Solid Dose, Semi-solids & Liquids, Sterile Fill-Finish
503 Neo Lab (NeoLabs Pharma)
United States
Sterile Fill-Finish
Compare Bora Pharmaceuticals Injectables with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.